Table 1. Simulation model inputs.

Model Input	Point Estimate	Low	High	Data Source	Distribution
Exenatide 2 mg
Effectiveness
DURATION-6 Trial Reduction in HbA1c	1.28%	1.18%	1.38%	[9]	Beta
Meta-Analysis Reduction in HbA1c	1.15%	1.00%	1.31%	[10]	Beta
Discontinuation Rate
Before Week 4	0%	0%	1%	[9]	Beta
After Week 4	13.23%	10.59%	15.88%	[9]	Beta
Drug Cost (2014 $USD)
Monthly cost of exenatide 2 mg (4 Pack)	$407	$367	$448	WAC	Normal
Adverse Event Rates
Patients Experiencing 1+ Adverse Events	61.39%	49.11%	73.67%	[9]	Beta
Gastrointestinal Disorders	39.93%	31.94%	47.92%	[9]	Beta
Liraglutide 1.8 mg
Effectiveness
DURATION-6 Trial Reduction in HbA1c	1.48%	1.38%	1.58%	[9]	Beta
Meta-Analysis Reduction in HbA1c	1.18%	1.04%	1.32%	[10]
Discontinuation
Before Week 4	3.33%	2.66%	4.00%	[9]	Beta
After Week 4	9.78%	7.82%	11.74%	[9]	Beta
Drug Cost (2014 $USD)
Monthly cost of liraglutide 1.8 mg (30 Pack)	$536	$482	$589	WAC	Normal
Needle cost	$9	$8	$10	Assumption	Normal
Adverse Event Rates
Patients Experiencing 1+ Adverse Events	64.89%	51.91%	77.87%	[9]	Beta
Gastrointestinal Disorders	54.7%	43.78%	65.66%	[9]	Beta
Other Costs
Adverse Event Costs (2014 $USD)
Gastrointestinal Disorders	$1,113	$890	$1,335	Expert Opinion	Normal

HbA1c = glycated hemoglobin; $USD = United States dollars; WAC = wholesale acquisition cost